Compounds > n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
Page last updated: 2024-11-01

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Cardiomyopathies

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Cardiomyopathies in 1 studies

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.

Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dowd, NP1
Scully, M1
Adderley, SR1
Cunningham, AJ1
Fitzgerald, DJ1

Other Studies

1 other study available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Cardiomyopathies

ArticleYear
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.
    The Journal of clinical investigation, 2001, Volume: 108, Issue:4

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonic Acid; Aspirin; Biomarkers; Cardiomyopa

2001